Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome

Anderson, H; Hopwood, Penelope; Stephens, RJ; Thatcher, N; Cottier, B.; Nicholson, M.; Milroy, Robert; Maughan, Tim; Falk, Stephen; Johanna Geertruida Bond, Marinde; Burt, P.A.; Connolly, C.K.; B McIllmurray, M; Carmichael, J

doi:10.1054/bjoc.2000.1307

Public

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome

Published in British Journal of Cancer • Aug 1, 2000

Authors:

H Anderson

Penelope Hopwood

RJ Stephens

Abstract

Three hundred patients with symptomatic, locally advanced or metastatic NSCLC not requiring immediate radiotherapy were enrolled into this randomized multicentre trial comparing gemcitabine + BSC vs BSC alone. Patients allocated gemcitabine received 1000 mg/m2 on days 1, 8 and 15 of a 28-day cycle, ...

Subject

Medicine

Gemcitabine

Randomized controlled trial

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!